MediWound Ltd. MDWD 深 沪
等待开盘 07-02 09:30:00 美东时间
14.82
+0.120
+0.82%
华盛通- 最 高15.10
- 今 开14.71
- 成交量 6.46万股
- 最 低 14.70
- 昨 收 14.70
- 总市值 1.90亿
- 52周最高 21.1099
- 市盈率 静 --
- 换手率 0.50%
- 52周最低 13.54
- 委 比 0.00%
- 总股本 1285.23万
- 历史最高 135.17
- 量 比 0.55
- 振 幅 2.72%
- 历史最低 7.10
- 每 手 1
- 风险率 1.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
Oppenheimer Maintains Outperform on MediWound, Lowers Price Target to $32
Oppenheimer analyst Francois Brisebois maintains MediWound (NASDAQ:MDWD) with a Outperform and lowers the price target from $33 to $32.
05-28 23:07
MediWound shares are trading lower after the company reported mixed Q1 financial results.
MediWound shares are trading lower after the company reported mixed Q1 financia...
05-28 02:19
MediWound Reports Q1 2026 Results: Full Earnings Call Transcript
MediWound (NASDAQ:MDWD) reported first-quarter financial results on Wednesday. ...
05-27 21:33
MediWound Affirms FY2026 Sales Guidance of $24.000M-$26.000M vs $24.759M Est
MediWound (NASDAQ:MDWD) affirms FY2026 sales outlook from $24.000 million-$26.000 million to $24.000 million-$26.000 million vs $24.759 million estimate.
05-27 19:02
MediWound Q1 EPS $(0.23) Beats $(0.64) Estimate, Sales $1.475M Miss $3.117M Estimate
MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.64) by 64.06 percent. This is a 228.57 percent decrease over losses of $(0.07) per share from the
05-27 19:01
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
MediWound reports that Vericel, its North America distributor for NexoBrid®, has been awarded a ten-year contract worth up to $197 million by the U.S. BARDA. The contract covers NexoBrid procurement, VMI system establishment, U.S. manufacturing facility design/validation, and development of a next-gen formulation and expanded indication for treating blast trauma injuries.
04-02 19:26
MediWound Files Annual Report on Form 20-F
MediWound Ltd., a global leader in enzymatic therapeutics for tissue repair,has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the SEC on March 5, 2026. The report is available on the SEC’s website and the company’s investor relations site. Shareholders can request a hard copy free of charge. MediWound’s FDA-approved product, NexoBrid®, is used for enzymatic removal of eschar in thermal burns and is markete...
03-05 21:30
MediWound Affirms FY2026 Sales Guidance of $24.000M-$26.000M
MediWound (NASDAQ:MDWD) affirms FY2026 sales outlook from $24.000 million-$26.000 million to $24.000 million-$26.000 million.
03-05 21:26
MediWound Publishes Corporate Presentation on Next-Generation Enzymatic Therapies for Non-Surgical Tissue Repair
MediWound Publishes Corporate Presentation on Next-Generation Enzymatic Therapies for Non-Surgical Tissue Repair MediWound Ltd. released a company presentation highlighting its enzymatic therapeutics platform for non-surgical tissue repair, featuring NexoBrid and the investigational candidate Eschar
03-05 20:32
